Bei Akademie registrieren
Novo-Nordisk, DK0062498333

Novo-Nordisk stock: pharmaceutical group at EUR 35.13 pre-market

Published on 10/23/2026 at 07:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk develops medicines for diabetes, obesity care and rare diseases. At Lang & Schwarz the stock trades pre-market at EUR 35.13 on October 23, 2026.

Business model and trading date

  • Novo Nordisk develops medicines for diabetes, obesity care and rare diseases.
  • The quoted trading date is October 23, 2026.
  • Novo-Nordisk stock trades pre-market at EUR 35.13 at 7:47 a.m. CEST at Lang & Schwarz on October 23, 2026.
Forscherin im Laborkittel an Pipette, Schwarzweiß-Reportagefoto, Labor
Novo Nordisk A/S (DK0062498333): Forscherin im Labor-Kittel bedient Pipette in dokumentarischem Schwarzweiß-Reportagefoto, Illustration mit AI erstellt.

Novo Nordisk A/S develops, manufactures and distributes medicines for diabetes, obesity care and rare disease markets. Novo-Nordisk stock trades pre-market at EUR 35.13 at 7:47 a.m. CEST at Lang & Schwarz on October 23, 2026.

Ahead of the Xetra open

The pre-market indication is dated for Friday's trading session. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Novo-Nordisk stock.

Company activity and market context

The company earns revenue from pharmaceutical products serving diabetes, obesity care and rare disease markets, with operations that also include specialized medical devices and digital diabetes-management solutions. Market context: Latest market reports.

More news and analysis on Novo-Nordisk stock

Disclaimer...
en | DK0062498333 | NOVO-NORDISK | boerse | 70396630 | bgmi